BioSight
Companies
Invivyd, Inc. logo

IVVD

NASDAQNEW HAVEN, CT
Invivyd, Inc.

Invivyd develops monoclonal antibody treatments for viral infectious diseases, with a focus on COVID-19. The company's lead product, PEMGARDA (pemivibart), received FDA emergency use authorization in March 2024, and Invivyd is advancing a next-generation COVID-19 candidate called VYD2311 through its REVOLUTION clinical program. Invivyd is in the clinical and early commercialization stage, with plans to introduce additional monoclonal antibody candidates as the virus evolves.

Price history not yet available for IVVD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar